Alrizomadlin is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. Alrizomadlin has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction.
Alrizomadlin (APG-115)
Brand name:
APG-115
Related Clinical Trials
Clinical Trial | Status | Age Group |
---|---|---|
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS | Recruiting | 18 years and older |
AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.